MRD in CLL: some answers, many questions

被引：3
|
作者：
Moreno, Carol [1 ]
Mora, Alba [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
BLOOD | 2021年 / 138卷 / 26期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; SURVIVAL;
D O I：
10.1182/blood.2021013435
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Wang et al compare the minimal residual disease (MRD) rate and outcome of patients with CLL treated with continuous ibrutinib plus 6 cycles of rituximab (IR) with that of those treated with FCR (fludarabine, cyclophosphamide and rituximab).(1) This study provides comparative data on the use of MRD in the management of CLL and emphasizes several pressing issues.
引用
收藏
页码：2746 / 2747
页数：2
相关论文
共 50 条
12345